Sir,

Serum vitamin D levels have been associated with migraine. Seasonal variation of serum vitamin D levels depicting higher levels in summer and lower levels in autumn-winter were matched with that of migraine attacks.\[[@ref1]\] A lower level of serum vitamin D was associated with migraine.\[[@ref2]\] Despite a probable relationship between migraine and serum vitamin D, clinical correlates associated with vitamin D deficiency were not clearly identified in migraine patients. Therefore, we identified vitamin D deficiency and its correlates in migraine patients for suggesting the role of vitamin D supplementation in migraine therapy.

We conducted a prospective, cross-sectional study. We invited new patients with migraine who visited our headache clinic. The Institutional Review Board of Kyungpook National University Hospital approved the study (approval number KNUH 2016-03-009). All participants gave written informed consent. We collected their clinical characteristics and conducted the Migraine Disability Assessment Scale,\[[@ref3]\] the Patient Health Questionnaire-9,\[[@ref4]\] the Generalized Anxiety Disorder-7,\[[@ref5]\] the Insomnia Severity Index,\[[@ref6]\] and the Fatigue Severity Scale.\[[@ref7]\] All eligible patients measured serum vitamin D levels by radioimmunoassay. Vitamin D deficiency is defined as a serum 25 (OH) D of less than 20 ng/ml.\[[@ref8]\] By this value, we divided patients into two groups as having vitamin D deficiency and having no deficiency. We identified factors associated with vitamin D deficiency by using univariate and multivariate analyses.

Initially, 380 new patients were visited our clinic. Of them, 92 patients were excluded due to concurrent vitamin D intake (*n* = 57), probable migraine (*n* = 18), refusal to the study (*n* = 15), younger age (*n* = 1), and older age (*n* = 1). Finally, 288 patients were eligible for the study. Their mean vitamin D level is 15.8 ± 5.7 ng/ml (range: 3.4-34.9 ng/ml). Of them, 240 patients (83.3%) had vitamin D deficiency. According to the existence of vitamin D deficiency, characteristics of patients are manifested in [Table 1](#T1){ref-type="table"}. Factors associated with vitamin D deficiency by univariate analyses are denoted in [Table 2](#T2){ref-type="table"}. Younger age, chronic migraine (CM), anxiety, and fatigue were associated with vitamin D deficiency. However, BMI, the amount of sunlight exposure, the date of blood sampling, headache intensity, and disability were not associated with it. Factors associated with vitamin D deficiency by multivariate analyses are listed in [Table 3](#T3){ref-type="table"}. CM (adjusted Odds Ratio \[AOR\] 4.038, 95% confidence interval \[CI\] 1.890-8.628, *P* \< 0.001) and younger age (AOR 1.031, 95% CI 1.006-1.058, *P* = 0.017) were selected.

###### 

Characteristics of migraine patients by serum vitamin D levels

                                 Mean±SD (range) or number (%)   
  ------------------------------ ------------------------------- -------------------
  Age (years)                    42.9±12.0 (20-64)               39.0±13.5 (20-68)
  Gender, female                 41 (85.4)                       194 (80.8)
  Education (years)              13.2±2.9 (6-18)                 13.0±3.1 (3-20)
  BMI                            22.0±2.7 (16-30)                22.5±3.4 (15-36)
  Sunlight exposure (/week)                                      
   Less than 1 hour              20 (41.7)                       98 (40.8)
   1 hour to less than 8 hours   22 (45.8)                       112 (46.7)
   8 hours or more               6 (12.5)                        30 (12.5)
  Date of blood sampling                                         
   October-March                 19 (39.6)                       125 (52.1)
   April-September               29 (60.4)                       115 (47.9)
  Type of migraine                                               
   Migraine with aura            3 (6.3)                         27 (11.3)
   Migraine without aura         45 (93.7)                       213 (88.7)
  Migraine chronicity                                            
   EM                            38 (79.2)                       125 (52.1)
   CM                            10 (20.8)                       115 (47.9)
  MOH                            3 (6.3)                         24 (10.0)
  Age at onset (years)           31.4±12.6 (13-58)               28.3±11.7 (6-60)
  Duration of migraine (years)   11.5±8.6 (0.3-31)               10.7±9.1 (0.5-42)
  Associated symptom                                             
   Nausea/vomiting               39 (81.3)                       204 (85.0)
   Photophobia                   24 (50.0)                       122 (50.8)
   Phonophobia                   31 (64.6)                       150 (62.5)
   Osmophobia                    20 (41.7)                       118 (49.2)
  VAS                            7.7±2.4 (0-10)                  7.5±2.3 (0-10)
  MIDAS (days)                   19.6±18.0 (0-70)                25.8±30.4 (0-181)
  Depression, \> 7 on            11 (22.9)                       82 (34.2)
  PHQ-9                                                          
  Anxiety, \> 5 on GAD-7         9 (18.8)                        89 (37.1)
  Insomnia, \>15 on ISI          5 (10.4)                        43 (17.9)
  Fatigue, \>3.21 on FSS         21 (43.8)                       146 (60.8)

25 (OH) D=25-hydroxyvitamin D; BMI=Body Mass Index; EM=episodic migraine; CM=chronic migraine; MOH=medication overuse headache; VAS=Visual Analog Scale; MIDAS=Migraine Disability Assessment Scale; PHQ.9=Patient Health Questionnaire-9; GAD.7=Generalized Anxiety Disorder-7; ISI=Insomnia Severity Index; FSS=Fatigue Severity Scale

###### 

Factors associated with serum vitamin D deficiency by univariate analyses

  Variable                              B        SE (B)   OR (95% CI)           *P*
  ------------------------------------- -------- -------- --------------------- -------
  Age                                   0.023    0.012    1.123 (0.998-1.048)   0.042
  Gender                                0.328    0.441    1.389 (0.586-3.294)   0.456
  Education                             0.028    0.053    1.029 (0.927-1.142)   0.596
  BMI                                   -0.053   0.051    0.948 (0.858-1.047)   0.295
  Sunlight exposure, less than 1 hour                                           
   Versus 1 hour to less than 8 hours   0.020    0.510    1.020 (0.375-2.773)   0.968
   Versus 8 hours or more               -0.018   0.504    0.982 (0.365-2.639)   0.972
  Date of blood sampling                0.506    0.322    1.659 (0.882-3.120)   0.116
  Migraine type                         0.643    0.630    1.901 (0.553-6.540)   0.308
  CM                                    1.252    0.378    3.496 (1.666-7.336)   0.001
  MOH                                   0.511    0.634    1.667 (0.481-5.774)   0.420
  Age at onset                          0.022    0.013    1.022 (0.996-1.049)   0.091
  Duration of migraine                  0.010    0.017    1.010 (0.976-1.044)   0.570
  Nausea/vomiting                       0.268    0.412    1.308 (0.584-2.930)   0.515
  Photophobia                           0.033    0.316    1.034 (0.556-1.922)   0.916
  Phonophobia                           -0.090   0.330    0.914 (0.479-1.745)   0.785
  Osmophobia                            0.303    0.320    1.354 (0.723-2.535)   0.343
  VAS                                   0.038    0.072    1.039 (0.902-1.197)   0.595
  MIDAS                                 -0.009   0.007    0.991 (0.978-1.004)   0.175
  Depression                            0.557    0.369    1.746 (0.846-3.601)   0.131
  Anxiety                               0.938    0.393    2.554 (1.182-5.520)   0.017
  Insomnia                              0.630    0.502    1.877 (0.702-5.017)   0.209
  Fatigue                               0.692    0.320    1.997 (1.067-3.736)   0.030

BMI=Body Mass Index; CM=chronic migraine; MOH=medication overuse headache; VAS=Visual Analog Scale; MIDAS=Migraine Disability Assessment Scale

###### 

Factors associated with serum vitamin D deficiency by multivariate analyses

  Variable   *B*      SE (*B*)   Adjusted OR (95% CI)   *P*
  ---------- -------- ---------- ---------------------- ---------
  Constant   -3.807   0.683      0.022                  \<0.001
  CM         1.396    0.387      4.038 (1.890-8.628)    \<0.001
  Age        0.031    0.013      1.031 (1.006-1.058)    0.017

CM=chronic migraine

We found major correlates for vitamin D deficiency were CM and younger age. The role of vitamin D deficiency on migraine chronicity has not been clearly identified. The pathogenic mechanism of migraine chronicity presumes to be associated with a neurotransmitter imbalance and upregulation of inflammatory pathways in CNS resulting in central amplification of peripheral pain signals.\[[@ref9]\] Vitamin D has anti-inflammatory effects in the body by reducing the release of pro-inflammatory cytokines and suppressing T-cell responses.\[[@ref10]\] So vitamin D deficiency may promote inflammatory pain mechanisms associated with CM. Another possibility is, as vitamin D deficiency was associated with emotional distress and fatigue in our patients, these symptoms is likely to work as migraine triggers and induce repetitive migraine attacks. Under these pathogenic roles of vitamin D deficiency, we presume serum vitamin D levels may be an important correlate for migraine chronicity. The lower level of vitamin D in the younger age may be explained by disproportionately greater time spent indoors and less time spent outdoors among younger compared with older individuals.\[[@ref11]\]

Although we cannot conclude vitamin D deficiency is specific for migraine patients due to the lack of data for healthy controls, we presume migraine chronicity may accentuate vitamin D deficiency. As vitamin D supplementation is effective for decreasing frequency of migraine attacks in EM,\[[@ref12]\] further studies should be warranted to prove the therapeutic efficacy of vitamin D supplementation on CM. In addition, the relationship between serum vitamin D levels and therapeutic response should be also identified.
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